Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM5 | P41594 | 2/20 | 0.40 |
| ▸ | CHRNA7 | P36544 | 2/20 | 0.40 |
| ▸ | CHRNA10 | Q9GZZ6 | 2/20 | 0.40 |
| ▸ | CHRNA9 | Q9UGM1 | 2/20 | 0.40 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.40 |
| ▸ | ACKR3 | P25106 | 3/20 | 0.39 |
| ▸ | IRAK4 | Q9NWZ3 | 7/20 | 0.38 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.38 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.38 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.38 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.38 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.37 |
| ▸ | FLT3 | P36888 | 1/20 | 0.37 |
| ▸ | MMP13 | P45452 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoroacetic Acid SCHEMBL2417740 | 0.94 | NTRK1 (0.38) | GRM5CHRNA7CHRNA10CHRNA9NTRK1 | |
| SCHEMBL222179 | 0.85 | IRAK4 (0.37) | IRAK4KCNH2HRH3 | |
| Cyclohexane SCHEMBL2428515 | 0.82 | HRH3 (0.40) | KCNH2HRH3 | |
| SCHEMBL2421213 | 0.82 | KMT2A (0.44) | HRH3 | |
| SCHEMBL2419695 | 0.82 | SMN1; SMN2 (0.48) | KCNH2HRH3 | |
| SCHEMBL222647 | 0.82 | KMT2A (0.41) | KCNH2HRH3 | |
| SCHEMBL219754 | 0.81 | PKM (0.51) | — | |
| Trifluoroacetic Acid SCHEMBL220163 | 0.80 | GPR6 (0.35) | IRAK4KCNH2HRH3 | |
| SCHEMBL223649 | 0.80 | KCNH2 (0.46) | KCNH2HRH3 | |
| SCHEMBL2428638 | 0.79 | HRH3 (0.38) | KCNH2HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2212282-B1 | SUBSTITUTED N-PHENYL-BIPYRROLIDINE CARBOXAMIDES AND THERAPEUTIC USE THEREOF | SANOFI SA (FR) | 2011-09-21 | — | — | EP | disclosed |
| US-20100173897-A1 | SUBSTITUTED N-PHENYL-BIPYRROLIDINE CARBOXAMIDES AND THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2010-07-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100173897-A1 | SUBSTITUTED N-PHENYL-BIPYRROLIDINE CARBOXAMIDES AND THERAPEUTIC USE THEREOF | HRH3, HRH4, CNR1 | GRM5 229/4885CHRNA7 66/4885CHRNA10 88/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.